期刊文献+

重视利巴韦林在慢性丙型肝炎抗病毒治疗中的应用 被引量:9

The importance of using ribavirin in treating chronic hepatitis C
原文传递
导出
摘要 当前干扰素是对慢性丙型肝炎治疗有确切抗丙型肝炎病毒(HCV)作用的药物,但单独使用普通干扰素治疗,仅有16%~20%的患者取得持续病毒应答(sustained virologic response,SVR),虽然开发的聚乙二醇化干扰素克服了普通干扰素存在的皮下注射后快速吸收、血清浓度波动大、系统分布广、肾脏清除率高和血清半衰期短,使得抗病毒程度不充分等缺陷,但也只能将SVR提高到30%~42%,即使增加聚乙二醇化干扰素的剂量也难以显著提高应答率。
作者 谢尧 李明慧
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2006年第12期930-931,共2页 Chinese Journal of Hepatology
关键词 肝炎 丙型 慢性 利巴韦林 干扰素 Hepatitis C, chronic Ribavirin Interferon
  • 相关文献

参考文献8

  • 1Di Bisceglie AM,Hoofnagle JH.Optimal therapy of hepatitis C.Hepatology,2002,36(5 Suppl 1):S121-S127.
  • 2Heathcote EJ,Shiffman ML,Cooksley WG,et al.Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.N Engl J Med,2000,343:1673-1680.
  • 3徐道振,谢尧,陆志檬,骆抗先,贾继东,王宇明,赵桂珍,张树林,张大志.聚乙二醇干扰素α-2a与干扰素α-2a治疗慢性丙型肝炎疗效、安全性的评估[J].中华传染病杂志,2004,22(4):221-224. 被引量:37
  • 4Lindahl K,Stahle L,Bruchfeld A,et al.High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.Hepatology,2005,41:275-279.
  • 5Kjaergard LL,Krogsgaard K,Gluud C.Interferon alfa with or without ribavirin for chronic hepatitis C:systematic review of randomised trials.BMJ,2001,323:1151-1155.
  • 6Fried MW,Shiffman ML,Reddy KR,et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med,2002,347:975-982.
  • 7Hadziyannis S J,Sette H Jr,Morgan TR,et al.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose.Ann Intern Med,2004,140:346-355.
  • 8Bronowicki JP,Ouzan D,Asselah T,et al.Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.Gastroenterology,2006,131:1040-1048.

二级参考文献8

  • 1Sharara AI.Diagnosis and management of chronic hepatitis C[].J Med Liban.1999
  • 2Zeuzem S,Welsch C,Herrmann E.Pharmacokinetics of peginter-ferons[].Seminars in Liver Disease.2003
  • 3Ferenci P.Peginterferon alfa-2a ( 40-kDa) ( Pegasys) for the treatment of patients with chronic hepatitis C[].International Journal of Clinical Practice.2003
  • 4Hadziyannis SJ,Papatheodoridis GV.Peginterferon-alpha2a (40 kDa) for chronic hepatitis C[].Expert Opinion on Pharmacotherapy.2003
  • 5Brouwer JT,Hansen BE,Niesters HG,et al.Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT[].Journal of Hepatology.1999
  • 6Vrolijk JM,Kwekkeboom J,Janssen HL,et al.Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection[].The Journal of Infectious Diseases.2003
  • 7Orito E.HCV genotype as a predictor of response to interferon therapy in patients with chronic hepatitis C[].Japanese Journal of Clinical Medicine.2001
  • 8Fried MW,Shiffman M,Sterling RK,et al.A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype[].The American journal of Gastroenterology.2000

共引文献36

同被引文献55

引证文献9

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部